Background. We previously reported that the RTS,S/AS02A vaccine had an acceptable safety profi e, was immunogenic, and demonstrated eff cacy against Plasmodium falciparum malaria disease for 21 months.
absorb the brunt of the disease, with approximately 350-550 million clinical episodes and 700,00 to 1.6 million deaths occurring annually, mostly among children !5 years of age [1, 2] .
The past decade has witnessed a renewed effort to study and control malaria. New tools are becoming available, and the development of a vaccine is considered to be a key component of future improved control activities. RTS,S (GlaxoSmithKline Biologicals [GSK]), a recombinant antigen, that is formulated with the AS02A Adjuvant System and that contains an oil-in-water emulsion and the immunostimulants QS21 (a triterpene glycoside purif ed from the bark of Quillaja saponaria) and 3D-MPL (3-deacylated monophosphoryl lipid A [MPL]), is currently the most clinically advanced malaria vaccine candidate in the world. RTS,S/AS02A specif cally targets the preerythrocytic stage of Plasmodium falciparum and has been shown to confer protection against experimental P. falciparum infection, delivered via laboratory-reared infected mosquitoes, in immunized malaria-naive volunteers and against natural infection in semi-immune adults [3] [4] [5] [6] [7] . Consecutive phase 1 trials in children aged 6-11 years and 1-5 years in The Gambia showed that the vaccine was safe, well tolerated, and immunogenic [3, 6, 8 ]. Short-term protection against infection (vaccine eff cacy, 71% [95% conf dence interval {CI}, 46%-85%] during the f rst 9 weeks of follow-up) was demonstrated in immunized adult men in The Gambia in 1998 [3] . Subsequently, a pediatric vaccine dose was selected and studied in a phase 1 trial of Mozambican children aged 1-4 years, in whom it was found to be safe, well tolerated, and immunogenic [9] .
In 2004, we reported the firs proof-of-concept study involving African children aged 1-4 years who were living in a P. falciparum-endemic area in Mozambique. During the fi st 6-months of follow-up in this double-blind, randomized, controlled trial, immunization with RTS,S/AS02A was associated with vaccine efficac (VE) of 29.9% (95% CI, 11.0%-44.8%;
) against clinical malaria, 45% (95% CI, 31.4%-55.9%; P p .004 ) against infection, and 57.7% (95% CI, 16.2%-80.6%; P ! .001 ) against severe malaria [10] . P p .019
An extended follow-up showed that, at 21 months after the firs dose, the risks of clinical malaria and severe malaria were reduced by 35.3% (95% CI, 21.6%-46.6%;
) and 48.6% P ! .001 (95% CI, 12.3%-71.0%;
), respectively, in the RTS,S/ P p .02 AS02A group [11] .
We recently completed a phase 1/2b clinical trial in infants living in a malaria-endemic area of Mozambique. Administration of RTS,S/AS02A, staggered with expanded program on immumization vaccines, showed that RTS,S/AS02A had a good safety profile was well tolerated and immunogenic, and was associated with a VE against new infection of 65.9% (95% CI, 42.6%-79.8%;
) [12] . P ! .001 Future deployment of any vaccine will depend on the level of VE and the duration of protection, both of which are critical elements of any target product profile The present study reports the long-term safety and efficac noted during 45 months of follow-up of Mozambican children who were 1-4 years of age at the time that they received a firs dose of either RTS,S/ AS02A or control vaccines.
METHODS

Study site.
The study was conducted at the Centro de Investigação em Saú de de Manhiça (CISM; Manhiça Health Research Centre) in Manhiça District, a rural area of Maputo Province, southern Mozambique, from April 2003 through May 2007. The characteristics of the area and the dates of malaria transmission have been described in detail elsewhere [13, 14] . Malaria transmission, mostly due to P. falciparum, is perennial, with marked seasonality. Anopheles funestus is the main vector, and the estimated entomologic inoculation rate for 2002 was 38 infective bites per person per year [10] . Combination therapy with amodiaquine and sulfadoxine pyrimethamine was the first-lin treatment used for uncomplicated malaria during the firs 2 years of the study, and it was replaced by the combination of sulfadoxine pyrimethamine plus artesunate in 2006. All antimalarial drugs were readily available at health care facilities in Mozambique throughout the study. Each participant received an insecticide-treated bednet during the study. Throughout the duration of the trial, indoor residual spray was promoted in the study area by the Mozambique Ministry of Health. Adjacent to the CISM is the Manhiça District Hospital, a 110bed referral health care facility. The district health network consists of an additional 8 peripheral health care posts and another rural hospital.
Study design. This study is a phase 2b, randomized controlled trial to assess the efficac , safety, and immunogenicity of 3 doses of the candidate RTS,S/AS02A malaria vaccine administered to children aged 1-4 years. The present study includes different follow-up periods (figu e 1). The initial doubleblind phase included study months 0-8.5. During this time period, and according to protocol, the investigators were unblinded, and a firs analysis of safety and efficac was performed and reported [10] . Study participants and case ascertainment mechanisms remained blinded, and follow-up was sustained, in accordance with protocol, in the single-blind phase occurring from study months 8.5 to 21 [11] . A subsequent new protocol was developed to expand follow-up of the safety and effi acy of the study cohorts from study months 21 to 45. The present study includes safety and efficac data for the entire study period from month 0 to month 45.
A total of 2022 healthy children aged 1-4 years were enrolled to receive either the candidate malaria vaccine or a comparison control vaccine. The parents or guardians of all participants provided written or thumb-printed informed consent before study enrollment. A member of the community acted as an impartial witness and countersigned the consent form to guarantee an adequate understanding of the study procedures by all guardians. Eligibility screening included a brief medical history, a physical examination, and blood sampling by f nger prick for hematologic and biochemical tests. Children did not undergo screening tests for human immunodef ciency virus (HIV) infection. Hepatitis B surface antigen (HBsAg) status and anti-HBsAg antibody levels were assessed at baseline but were not criteria for exclusion from the trial. Other serologic markers of hepatitis B status were not assessed.
Children were randomized 1:1 to receive RTS,S/AS02A (in a 0.25-mL dose) or the control vaccines. The RTS,S/AS02A candidate vaccine was administered intramuscularly in the deltoid region of alternating arms, starting with the left arm, according to a 0-, 1-, and 2-month schedule. Children in the control group who were у24 months of age received 3 pediatric doses (0.5 mL) of hepatitis B vaccine (Engerix-B; GSK). Children !24 months of age received 2 pediatric doses of 7-valent pneumococcal conjugate vaccine (Prevenar; Wyeth Lederle Vaccines), which was administered at the firs and third vaccinations, and 1 dose of Haemophilus influenza type B vaccine (Hiberix; GSK Biologicals), which was administered at the second vaccination.
Children were enrolled in 2 cohorts to measure the VE against clinical malaria disease and malaria infection. In cohort 1 (from the Manhiça area), 1605 participants were monitored using passive surveillance, to detect clinical episodes of malaria, and safety surveillance, until month 45. In cohort 2 (from the Ilha Josina village), 417 participants were monitored using active surveillance, to detect malaria infection through visits that started 14 days after administration of dose 3, continued every 2 weeks for 2.5 months, and then continued monthly for an additional 2 years. At the end of the single-blind phase, new informed consent was obtained to continue follow-up for 2 more years. Surveillance for this cohort was continued through a health care facility-based passive case-detection system, to monitor safety. The protocol (Investigational New Drug no. BB-IND 10514) was approved by the Mozambican National Ethics Review Committee, the Hospital Clínic of Barcelona (University of Barcelona) Ethics Review Committee, and the PATH Human Subjects Protection Committee. The trial was conducted in accordance with International Conference on Harmonisation of Good Clinical Practice guidelines and was monitored by GSK. A local safety monitor and a data and safety monitoring board closely reviewed the conduct and safety data of the trial.
Study procedures. Vaccines were administered at the Manhiça and Ilha Josina health care centers. Vaccine safety was evaluated using active and passive follow-up [15] .
A serious adverse event (SAE) was define as any medical event that resulted in death, was life-threatening, required inpatient hospitalization, or resulted in persistent or signifi ant disability or incapacity. Investigators monitored participants with SAEs until the event had resolved or until month 45 of surveillance. Deaths that occurred at home were investigated by a review of all available medical records and through a verbal autopsy.
Statistical methods. Safety analysis was based on intentionto-treat (ITT) analysis of study participants included in both cohorts 1 and 2 during months 0-45. Analyses of VE against clinical malaria were based on cohort 1 study participants who were compliant with study procedures (ie, the according-toprotocol [ATP] cohort for analysis) from month 2.5 to month 45 during the study period A child with a clinical episode was define as a child who presented to a health care facility with an axillary temperature of у37.5ЊC and P. falciparum asexual-stage parasitemia of у2500 parasites/mL (as per primary case definition) A child requiring admission to the hospital for malaria was define as a child with P. falciparum asexual-stage parasitemia for whom malaria was judged to be the sole cause of illness or a substantial contributing factor. All cases of severe malaria were defi ed by the presence of asexual P. falciparum parasitemia in a severely ill child, with there being no other more-probable cause of illness. Severe malaria was define by the presence of any the following conditions: severe malaria anemia (packed-cell volume, !15%), cerebral malaria (Blantyre coma score, !2), and/ or severe disease of other body systems (eg, multiple seizures [у2 generalized convulsions in the previous 24 h], prostration [define as an inability to sit unaided], hypoglycemia [!2.2 mmol/L], clinically suspected acidosis, or circulatory collapse) [16]. All hospital admissions were independently reviewed by 2 groups of clinicians, to determine whether malaria was the cause of the admissions and whether the cause fulfille the definitio of severe malaria. Discrepancies were resolved by consensus.
For the efficac analyses, except for analyses of hospital admissions, the time at risk was calculated with absences from the study area and antimalarial drug use both considered. For analysis of multiple episodes of clinical malaria, a subject was not considered to be susceptible for 28 days after the previous episode. After receiving malaria treatment, a child was not considered to be at risk for an arbitrary period of 28 days after receiving sulfadoxine pyrimethamine, 7 days after chloroquine alone, 7 days after quinine alone, 7 days after amodiaquine, and 20 days after artemether plus lumefantrine.
For the time to a firs or only episode of clinical malaria, VE was assessed using Cox regression models and was defi ed as:
. The VE was adjusted for prede-(1 Ϫ hazard ratio) ϫ 100 fine covariates of age, bed net use, geographic area (administrative divisions), and distance from a health care center. Cox regression assumes proportional hazards throughout follow-up. This assumption was checked graphically by plotting per group the log of the cumulative hazard against the log of time [17] , as well as by using a test based on the Schoenfeld residuals and time-dependent Cox regression models [18] .
For multiple episodes of clinical malaria and hospital admission, the group effect was assessed using Poisson regression models with normal random intercepts, including the time at risk as an offset variable.
Differences in the proportions of children with at least 1 episode of severe malaria disease and the prevalence of asexual P. falciparum at each cross-sectional survey were compared using Fisher's exact test. For severe malaria, VE was calculated as , with the exact 95% confidenc interval de-1 Ϫ risk ratio termined using StatXact PROCs for SAS, version 6 (Cytel Statistical Software).
The humoral immune response against P. falciparum was assessed as described elsewhere by determining titers of antibody to the circumsporozoite protein. Seropositivity was define as anti-circumsporozoite protein titers of у0.5 EU/mL. Analyses were performed using SAS software (version 8; SAS) and STATA software (version 9.0; Stata).
RESULTS
For the safety analysis (surveillance months 0-45), a total of 2022 children aged 1-4 years were recruited and randomized to the RTS,S/AS02A group and the control group (1605 children for cohort 1 and 417 children for cohort 2). A total of 1465 subjects (72.5%; 1142 subjects in cohort 1 and 323 subjects in cohort 2) completed the follow-up to study month 45. For the efficac analyses (months 2.5-45), including only those participants in cohort 1, a total of 1490 (73.7%) of 2022 children completed the follow-up (figu e 2).
Over the 45-month surveillance period analyzed for the intent-to-treat cohort, 639 SAEs classifie according to the preferred term in the Medical Dictionary for Regulatory Activities [19] were noted in 235 subjects who received the RTS,S/AS02A vaccine, and 770 SAEs were noted in 326 subjects who received the control vaccines (table 1). The pattern of the causes of SAEs observed in this trial is similar to the morbidity background of the area. The most important diseases are malaria, anemia, NOTE. The 1605 participants in cohort 1 were monitored using passive surveillance, to detect clinical episodes of malaria, and safety surveillance. Vaccine efficacy estimates were adjusted by age at baseline, bed net use at baseline, distance from health care facility, and geographic region. CI, confidence interval; PYAR, person-years at risk. gastroenteritis, and pneumonia. During this period, 62 cases of severe malaria were experienced by 4.6% (95% CI, 3.4%-6.1%) of the study participants who received RTS,S/AS02A. In the control group, there were 83 cases of severe malaria among 7.0% (95% CI, 5.5%-8.8%) of the study participants. Blood transfusions were performed for 58 subjects (2.7% of patients in the group receiving study vaccine and 3.1% of patients in the control group). There were 34 deaths, with 12 (1.2% [95% CI, 0.6%-2.1%]) occurring in the RTS,S/AS02A group and 22 (2.2% [95% CI, 1.4%-3.35%]) occurring in the control group (
). Six of these deaths were judged to be associated P p .087 with malaria: 1 occurred in the RTS,S/AS02A group, and 5 occurred in control group. No SAE or death was considered to be associated with vaccination.
VE. In the VE analyses (VE analysis for the according-toprotocol cohort for months 2.5-45 [ATP {2.5-45} ]), 677 children had firs or only clinical episodes that met the primary case definition Of these, 307 were in the RTS,S/AS02A group and 370 were in the control group, yielding a crude VE estimate of 25.6% (95% CI, 13.4%-36.0%;
) and an adjusted P ! .001 VE (2.5-45) of 30.5% (95% CI, 18.9%-40.4%;
) (fi ure P p! .001 3). The VE estimates obtained using several case def nitions based on different parasite-density cutoff levels are shown in table 2. The adjusted VE (2.5-45) of surveillance, including all clinical episodes, was 25.6% (95% CI, 11.9%-37.1%;
). P ! .001 In the RTS,S/AS02A group ( ), there were 29 children n p 745 who had у1 episode of severe malaria, compared with 47 children in the control group ( ) (VE, 38.3% [95% CI, n p 745 3.4%-61.3%];
). The number of hospital admissions P p .045 due to all causes was also lower for the RTS,S/AS02A group than for the control group (175 vs 194 admissions), and the VE was 22.2% (95% CI, Ϫ3.8% to 41.7%;
). The VE P p .088 against malaria resulting in hospitalization was 23.0% (95% CI, Ϫ1.7% to 41.9%;
). P p .078 Analysis of VE over different follow-up periods showed a VE of 16.8% over months 21-33 (95% CI, Ϫ2.5% to 32.4%;
) and a VE of 11.8% over months 33-45 (95% CI, P p .084 Ϫ20.1% to 35.2%;
). There is a trend toward lower P p .426 estimates of efficac over the latter follow-up periods, but the proportionality of the hazard assumption did not fi d evidence of waning efficac either by graphical inspection of the plot of with log of the survival time, the time-log [Ϫlog(survival time)] dependent Cox models, or the test based on the Schoenfeld residuals ( ). P p .210 Anti-circumsporozoite protein response and parasitemia. Anti-circumsporozoite protein antibody levels were still ∼30fold higher than prevaccination levels in cohort 1 at month 45 in the RTS,S/AS02A group, with a geometric mean titer (GMT) of 8.9 (95% CI, 7.8-10.1), whereas most of the children in the control group had a GMT of 0.3 (95% CI, 0.3-0.3). At least 96% of subjects in the RTS,S/AS02A group were seropositive for anti-circumsporozoite protein antibodies at month 45.
The prevalence of asexual-stage parasites was lower in the RTS,S/AS02A group than in the control group, in the yearly cross-sectional surveys that were performed (figu e 4 
DISCUSSION
The present study reports what is, to our knowledge, the fi st long-term follow-up of a pediatric malaria vaccine trial in Africa. Over a 45-month period, the candidate vaccine had an acceptable safety profile with significantl less SAEs and a trend toward a reduced mortality rate among individuals in the RTS,S/AS02A group.
Previous reports confi med efficac during an initial 6month follow-up as well as sustained protection up to 21 months of follow-up. Analysis up to 45 months allows us to exclude the theoretical risk that partial protection with this vaccine could have impaired acquisition of natural immunity and that subsequent loss of vaccine-induced protection could be followed by a rebound in the risk of clinical malaria among previously protected children.
It is challenging to assess the duration of protection against a communicable disease when repeated infections and clinical episodes are required to slowly build up naturally acquired immunity, and when the risk of malaria consequently is age dependent. Indeed, over the past 2 years, the incidence of clinical malaria in the control group decreased from 0.37 episodes/ person-years at risk (during follow-up from months 21 to 33) to 0.15 episodes/person-years at risk (during follow-up from months 33 to 45). Analysis of efficac broken down into 12-month periods yields estimates that show a tendency toward decreasing efficac from 30% to 11%, with overlapping confidenc intervals that are wider at the end indicating less precision on the estimate at the end of the study. The statistical method used to evaluate the proportionality of the hazard assumption showed no evidence of waning efficac , but because the study was not designed to have sufficien power to evaluate this, it could reflec a lack of power to detect it.
On the other hand, the prevalence of parasites at the end of the 45-month follow-up was significantl lower in the vaccine group than in the control group. Given that the prevalence of P. falciparum asexual-stage parasitemia must reflec the recent risk of infection, we interpret this findin as a strong indication that significan efficac remains at the end of the 45-month follow-up. VE against clinical malaria and against severe malaria over the entire follow-up was 30.5% (95% CI, 18.9%-40.4%) and 38.3% (95% CI, 3.4%-61.3%), respectively. VE against all clinical episodes was 25.6% (95% CI, 11.9%-37.1%;
). In P ! .001 other words, immunization with RTS,S/AS02A reduced the burden of malaria during this period by approximately onequarter.
These exciting results confi m the potential of developing malaria vaccines that may influenc relevant end points of clinical and public health and that may consequently reduce the unacceptable burden of malaria in African children. Together with recently reported data showing a favorable safety prof le and a proof-of-concept efficac of 65% in reducing the risk of new infections when vaccine is administered to young infants at 10, 14, and 18 weeks of age or coadministered with routine EPI vaccine [12, 20] , these results strengthen the rationale for advancing toward a phase 3 trial aiming to register RTS,S/AS as the fi st malaria vaccine.
